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OBJECTIVES:Major Depressive Disorder (MDD) is an important and growing health
problem in Turkey. Inclusion of a new drug in the positive list for its treatment
requires the proof of cost effectiveness. The objective of this study was to assess
the cost effectiveness of Agomelatine versus Venlafaxine and Duloxetine in treat-
ment of MDD in Turkey. The study was undertaken from the payer perspective.
METHODS: A discrete event model, already validated by European health author-
ities was used to compare Agomelatine with Venlafaxine and Duloxetine. An indi-
rect comparison was made between Agomelatine and Duloxetine. In order to re-
flect the real clinical practice, themodel defined 3-6months of treatment, however
the maintenance phase, defined as the recommended time to prevent eventual
recurrences, was modeled longer (12 weeks and 24 weeks).The clinical outcome
was measured as life years in remission. All direct costs for the year 2011 were
taken into account. Costs and benefitswere discounted by 3%and robustness of the
results were tested by Monte Carlo simulation. RESULTS: Incremental Cost Effec-
tiveness Ratios(ICER) were calculated and results were displayed as cost per addi-
tional life year in remission. The ICER was calculated as –18,799 TL/year in remis-
sion for Agomelatine versus Venlafaxine and – 27,453 TL/year in remission for
Agomelatine versus Duloxetine. CONCLUSIONS: Agomelatine dominated Venla-
faxine and Duloxetine in treatment of MDD in Turkey. Sensitivity analyses re-
vealed that the results were robust.
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OBJECTIVES: Due to rapid aging, South Korea is expected to be the world’s second
oldest country by 2050. Dementia has emerged as a major health problem among
old people in South Korea, and since 2010 the Korean Ministry of Health and Wel-
fare (MOHW) has implemented “National Program for Screening Dementia (NPSD)”
as one of the welfare services for the aged. This study aimed to evaluate the cost-
effectiveness of early diagnosis and treatment of dementia. METHODS: A Markov
model was developed using a societal perspective and a 10-year time horizon.
Simulations were performed for hypothetical cohorts of those aged 65, 70, 75, 80
years. Data sources for model parameters included the NPSD database for cohort
characteristics; the National Health Insurance claims database and survey for de-
mentia costs; the meta-analysis for the treatment effect; and published data for
other epidemiology data. Cost per quality-adjusted life-year (QALY) gained from
screening compared with no screening was calculated from 10-year costs and ac-
cumulated QALYs for each strategy. RESULTS: Screening strategies showed a cost
per QALY gained ranging from 38 million Korean Won (KRW, equivalent to
US$32,000) to 41 million KRW (US$ 34,000), depending on the ages selected for
screening. These results were most sensitive to estimates of direct health care
costs and the severity of dementia among those screened. CONCLUSIONS: These
analyses suggest that NPSD need to improve the cost-effectiveness of screening by
identifying patients with mild dementia rather than severe dementia. The early
diagnosis and treatment of dementia failed to achieve cost saving. This could be
explained by some reasons that there is no such a dramatic difference among net
costs of dementia by disease stage in SouthKorea compared to other countries, and
that the benefits of current therapies are marginal.
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OBJECTIVES: Bipolar disorder (BPD) is highly prevalent and is associated with a
significant economic burden. Antipsychotic drugs are one of themainstream treat-
ments for BPD. Asenapine is a new antipsychotic approved in Canada for the treat-
ment to be used in monotherapy or co-therapy in BPD-I and schizophrenia.
Asenapine has shown a comparable efficacy profile to olanzapine. However, in
contrast to olanzapine, it is associated with a favourable metabolic profile and
minimal weight gain. The objective of this study was to assess, from a Canadian
perspective, the economic impact of asenapine compared to olanzapine in the
treatment of BPD-I. METHODS: A combined decision tree and Markov model was
constructed to assess the cost-utility of asenapine compared with olanzapine. The
decision tree takes into account the occurrence of extrapyramidal symptoms (EPS),
the probability of switching to a different antipsychotic, and the probability of
gainingweight. The treatment used in case of switchwas aripiprazole. TheMarkov
model comprises the following states: long-term metabolic complications (diabe-
tes, hypertension, CHDs, and stroke), fatal stroke, fatal CHD, and death by suicide
or other causes. Due to limited data, asenapine was compared with olanzapine
only. Analyses were conducted from both a CanadianMinistry of Health (MoH) and
a societal perspective over a five-year time horizonwith yearly cycles. RESULTS: In
the treatment of BPD-I, asenapine is a dominant strategy over olanzapine from
both a MoH and a societal perspective. Results of the probabilistic sensitivity anal-
ysis indicated that asenapine remains a dominant strategy in 99.2% of the simula-
tions, and this result is robust to the many sensitivity analyses performed.
CONCLUSIONS: This economic evaluation demonstrates that asenapine is a cost-
effective strategy compared to olanzapine in the treatment of BPD-I in Canada.
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OBJECTIVES: Asenapine is a new antipsychotic approved in Canada for the treat-
ment of schizophrenia (SCZ) and bipolar disorder I as monotherapy and co-ther-
apy. Asenapine has shown a comparable efficacy profile to atypical antipsychotics.
In contrast, however, tomost atypical antipsychotics, it is associatedwith a favour-
able metabolic profile as well as with a minimal weight gain. The objective was to
assess, from a Canadian perspective, the economic impact of asenapine compared
to olanzapine, quetiapine, ziprazidone, aripiprazole.METHODS: A combined deci-
sion tree andMarkovmodel was constructed to assess the cost-utility of asenapine
compared with other atypical antipsychotics. The decision tree takes into account
the occurrence of extrapyramidal symptoms (EPS), the probability of switching to a
different antipsychotic, and the probability of gaining weight. The Markov model
comprises the following states: long-term metabolic complications (diabetes, hy-
pertension, CHDs, and stroke), fatal stroke, fatal CHD, and death by suicide or other
causes. In the base-case analysis, asenapinewas compared to olanzapine. Asenap-
ine was also compared with atypical antipsychotics commonly used in Canada.
Analyses were conducted from both a Canadian Ministry of Health (MoH) and a
societal perspective over a five-year time horizon with yearly cycles. RESULTS: In
the treatment of SCZ, asenapine is a dominant strategy over olanzapine from both
an MoH and a societal perspective, and this result is robust to the many sensitivity
analyses performed. Compared to quetiapine, asenapine is also a dominant strat-
egy. Furthermore, asenapine has a favourable economic impact compared to zipra-
zidone and aripripazole, as these antipsychotics are not cost effective compared to
asenapine, with an incremental cost-effectiveness ratio of $63,204/QALY and
$1,485,625/QALY from a MoH perspective and $62,432/QALY and $1,485,623/QALY
from a societal perspective, respectively. CONCLUSIONS: This economic evalua-
tion demonstrates that asenapine is a cost-effective strategy compared to olanzap-
ine and to most atypical antipsychotics used in Canada.
PMH39
IMPACT OF ADHERENCE TO ANTI-DEPRESSANT MEDICATION ON SHORT-TERM
DISABILITY COSTS IN AN EMPLOYER POPULATION
Wright D1, Hagen S1, Finch R2, Edington D1
1University of Michigan, Ann Arbor, MI, USA, 2National Business Group on Health, Washington,
DC, USA
OBJECTIVES: According to the Centers for Disease Control, nearly twenty percent
of the American workforce has some type of mental disorder. Depression is espe-
cially prevalent, and antidepressant use in the United States. is common; today,
one in ten Americans over the age of 12 takes an antidepressant medication. This
study assesses the relationships between antidepressant medication adherence
and short-term disability costs in a large manufacturing company. METHODS: A
retrospective analysis of pharmacy claims was conducted to identify individuals
within a largemanufacturing companywhowere continuously eligible for a three-
year time frame (between 2001 - 2007) and who received a prescription for an
antidepressant during that time. In those cases where an individual’s eligibility
spanned a longer time period, the most recent three-year span was chosen. The
resulting sample included both treatment-naïve and treatment-experienced pa-
tients.Medical, pharmacy, and short-termdisability costswere calculated for a one
year follow-up. Adherence was measured using proportion of days covered (PDC),
where a PDC80 was considered adherent. Multi-variable linear regression was
used to examine the relationships between cost and adherence, controlling for
patient demographics (age, gender, and job type) and Charlson co-morbidity score.
RESULTS: Among the 14,737 individuals in the study, the mean adherence to an-
tidepressants was 49%, and 28% (N4178) of the study population had a PDC80.
The average total medical/pharmacy costs were higher for the adherent patients.
Individuals who were adherent to their antidepressant medications, howwever,
had lower short-term disability costs ($2129/year) than did the non-adherent
($2440/year). CONCLUSIONS: In general, patients who were adherent to their an-
tidepressant regimens had lower short-term disability costs than did the non-
adherent. Employers concerned with the impact of depression on their employee
costs should pay particular attention to this association between antidepressant
adherence and short-term disability.
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OBJECTIVES: The purpose of this study was to estimate the effect of clinical and
demographic patient characteristics, and insurance status on hospital charges asso-
ciated with opioid abuse or misuse in the United States. METHODS: Data for this
study were derived from the 2006, 2007, and 2008 Healthcare Cost and Utilization
Project’s Nationwide Emergency Departments Sample (HCUP-NEDS). Events and
charges related to opioid abuse, dependence, or poisoning overall and by insurance
status (Medicaid, Medicare, private insurance, or self-pay) were estimated using ICD-
9-CM codes 304.0X, 304.7X, 305.5X, 965.00, 965.02, and 965.09, accounting for the com-
plex sampling of theHCUP-NEDS. Chargeswere adjusted using the 2010Medical Con-
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